Screener
Regeneron Pharmaceuticals REGN Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $4.29B+16.7% | $3.61B+19.0% | $3.88B+2.5% | $3.75B+0.9% | $3.68B+3.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.63B+14.8% | $1.54B+16.3% | $1.63B+15.2% | $1.48B+16.0% | $1.42B+18.5% | ||
| $662.1M+4.4% | $647.7M+2.3% | $775M-2.2% | $657.8M-7.9% | $634.2M-16.4% | ||
| $3B+15.5% | $2.96B+21.6% | $3B+7.3% | $2.73B+7.3% | $2.6B+4.8% | ||
| $1.29B+19.8% | $642.9M+8.7% | $879.9M-11.1% | $1.03B-12.9% | $1.08B+0.9% | ||
| 30.1%+0.8pp | 17.8%-1.7pp | 22.7%-3.5pp | 27.3%-4.4pp | 29.4%-0.8pp | ||
| $11M+206% | $12.9M+48.3% | $12.2M+16.2% | $19.3M+39.9% | $3.6M-75.7% | ||
| $234.3M-46.7% | $188.3M-39.9% | $163.8M— | $736.5M+135% | $439.2M-21.4% | ||
| $1.53B+0.6% | $831.2M-8.2% | $1.04B+8.9% | $1.76B+18.1% | $1.52B-6.7% | ||
| $230.9M+81.7% | $104M+8.0% | $199.1M+393% | $303.3M+99.0% | $127.1M-35.1% | ||
| $1.3B-6.8% | $727.2M-10.1% | $844.6M-8.0% | $1.46B+8.9% | $1.39B-2.8% | ||
| 30.2%-7.6pp | 20.2%-6.5pp | 21.7%-2.5pp | 38.9%+2.9pp | 37.9%-2.5pp | ||
| $12.23-4.5% | $6.75-7.2% | $7.87-3.0% | $13.62+18.0% | $12.81+3.2% | ||
| $1.42B+16.7% | $766.1M+6.6% | $1.02B-8.2% | $1.16B-10.6% | $1.21B+2.0% | ||
| 33%0.0pp | 21.2%-2.5pp | 26.4%-3.1pp | 31%-4.0pp | 33%-0.5pp | ||
| $1.29B+19.8% | $642.9M+8.7% | $879.9M-11.1% | $1.03B-12.9% | $1.08B+0.9% |
FAQ
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $15.5B in revenue over the trailing twelve months, up 9.3% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 27.9% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 94.9% and operating margin is 24.7%, with a 27.9% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $40.47.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
